Bruijning-Verhagen, Pvan Dongen, J A PVerberk, J D MPijnacker, Rvan Gaalen, R DKlinkenberg, Dde Melker, H EMangen, M-J J2018-11-192018-11-192018Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting. 2018, 16 (1):168 BMC Med1741-70153019679410.1186/s12916-018-1134-3http://hdl.handle.net/10029/622244Since 2013, a biennial rotavirus pattern has emerged in the Netherlands with alternating high and low endemic years and a nearly 50% reduction in rotavirus hospitalization rates overall, while infant rotavirus vaccination has remained below 1% throughout. As the rotavirus vaccination cost-effectiveness and risk-benefit ratio in high-income settings is highly influenced by the total rotavirus disease burden, we re-evaluated two infant vaccination strategies, taking into account this recent change in rotavirus epidemiology.enArchived with thanks to BMC medicinehttp://creativecommons.org/licenses/by/4.0/ChildChild, PreschoolCost-Benefit AnalysisFemaleHumansInfantInfant, NewbornMaleRisk AssessmentRotavirus InfectionsRotavirus VaccinesSocioeconomic FactorsArticleBMC Med 2018; 16(1):168